Guggenheim on Phathom Pharmaceuticals (PHAT): 'Our NPV analysis suggests fair value in the $12-14 range'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $12.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).The analyst comments "Recall ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
